NK NantKwest Inc.

1.18
-0.03  -2%
Previous Close 1.21
Open 1.22
Price To Book 0.58
Market Cap 93486778
Shares 79,226,083
Volume 194,443
Short Ratio
Av. Daily Volume 243,120

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.
haNK
Pancreatic cancer vaccine
80% Disease Control noted - November 7, 2018.
haNK
Triple Negative Breast Cancer (TNBC)
Phase 2 initiation announced January 9, 2018.
haNK + avelumab + N-803
Merkel cell carcinoma (MCC)

Latest News

  1. Is the Options Market Predicting a Spike in NantKwest (NK) Stock?
  2. NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
  3. Soon-Shiong’s NantCell gets $30 million from Celgene
  4. NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
  5. Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
  6. Is Nantkwest Inc (NK) Going to Burn These Hedge Funds?
  7. NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
  8. Here's Why NantKwest Skyrocketed 26.4% Today
  9. Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.
  10. NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
  11. NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
  12. NantKwest Sees Hammer Chart Pattern: Time to Buy?
  13. NantKwest to Present at 2018 Cantor Global Healthcare Conference
  14. Who Are The Top Investors In NantKwest Inc (NASDAQ:NK)?
  15. Citigroup Upgrades NantKwest, But Finds Six Reasons To Stay On Sidelines
  16. NantKwest Names Sonja Nelson Chief Financial Officer
  17. Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO